Maxim Group set a $5.00 price objective on Adamis Pharmaceuticals (NASDAQ:ADMP) in a report released on Tuesday morning. The brokerage currently has a buy rating on the specialty pharmaceutical company’s stock.
A number of other equities research analysts have also recently weighed in on the company. Raymond James Financial set a $7.00 price objective on Adamis Pharmaceuticals and gave the company a buy rating in a research note on Friday, February 23rd. Zacks Investment Research raised Adamis Pharmaceuticals from a sell rating to a hold rating in a research note on Tuesday, January 16th. B. Riley set a $10.00 price objective on Adamis Pharmaceuticals and gave the company a buy rating in a research note on Thursday, November 30th. Finally, ValuEngine cut Adamis Pharmaceuticals from a hold rating to a sell rating in a research note on Thursday, November 30th. One investment analyst has rated the stock with a sell rating, one has given a hold rating and three have assigned a buy rating to the company. The company has an average rating of Hold and an average price target of $7.33.
Shares of Adamis Pharmaceuticals (NASDAQ ADMP) opened at $4.25 on Tuesday. Adamis Pharmaceuticals has a one year low of $2.35 and a one year high of $6.45. The company has a quick ratio of 3.79, a current ratio of 3.93 and a debt-to-equity ratio of 0.06. The firm has a market capitalization of $154.63, a price-to-earnings ratio of -6.07 and a beta of 0.36.
TRADEMARK VIOLATION NOTICE: This story was first published by Ticker Report and is the property of of Ticker Report. If you are accessing this story on another publication, it was stolen and reposted in violation of international copyright & trademark laws. The correct version of this story can be viewed at https://www.tickerreport.com/banking-finance/3253231/maxim-group-analysts-give-adamis-pharmaceuticals-admp-a-5-00-price-target.html.
About Adamis Pharmaceuticals
Adamis Pharmaceuticals Corporation is a pharmaceutical company. The Company is engaged in the development of its specialty pharmaceutical products. The Company is developing various products in the allergy and respiratory markets, including a dry powder inhaler technology that it acquired from 3M Company (3M).
Receive News & Ratings for Adamis Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Adamis Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.